Iterum Therapeutics PLC
NASDAQ:ITRM
Income Statement
Earnings Waterfall
Iterum Therapeutics PLC
Revenue
|
0
USD
|
Operating Expenses
|
-47.5m
USD
|
Operating Income
|
-47.5m
USD
|
Other Expenses
|
9.1m
USD
|
Net Income
|
-38.4m
USD
|
Income Statement
Iterum Therapeutics PLC
Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||
Revenue |
1
N/A
|
1
+37%
|
1
+27%
|
1
+10%
|
1
-11%
|
1
-17%
|
1
-26%
|
0
-47%
|
0
-86%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||||||||
Operating Expenses |
(30)
|
(37)
|
(46)
|
(63)
|
(77)
|
(86)
|
(97)
|
(103)
|
(102)
|
(94)
|
(75)
|
(51)
|
(32)
|
(25)
|
(24)
|
(22)
|
(25)
|
(26)
|
(27)
|
(29)
|
(30)
|
(49)
|
(52)
|
(44)
|
(47)
|
|
Selling, General & Administrative |
(4)
|
(5)
|
(6)
|
(7)
|
(9)
|
(10)
|
(11)
|
(12)
|
(11)
|
(11)
|
(12)
|
(11)
|
(11)
|
(11)
|
(12)
|
(13)
|
(14)
|
(14)
|
(14)
|
(14)
|
(13)
|
(11)
|
(9)
|
(8)
|
(7)
|
|
Research & Development |
(26)
|
(32)
|
(40)
|
(55)
|
(69)
|
(75)
|
(86)
|
(91)
|
(91)
|
(83)
|
(64)
|
(40)
|
(21)
|
(14)
|
(11)
|
(9)
|
(11)
|
(12)
|
(13)
|
(15)
|
(18)
|
(21)
|
(26)
|
(36)
|
(40)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(17)
|
(17)
|
0
|
0
|
|
Operating Income |
(29)
N/A
|
(36)
-23%
|
(45)
-25%
|
(62)
-37%
|
(77)
-24%
|
(85)
-11%
|
(97)
-14%
|
(103)
-6%
|
(102)
+1%
|
(94)
+7%
|
(75)
+20%
|
(51)
+33%
|
(32)
+37%
|
(25)
+22%
|
(24)
+5%
|
(22)
+6%
|
(25)
-10%
|
(26)
-6%
|
(27)
-4%
|
(29)
-8%
|
(30)
-4%
|
(49)
-61%
|
(52)
-6%
|
(44)
+15%
|
(47)
-8%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(6)
|
(10)
|
(17)
|
(109)
|
(90)
|
(76)
|
(67)
|
31
|
17
|
3
|
3
|
(2)
|
(5)
|
13
|
10
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(2)
|
(3)
|
(3)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(17)
|
(17)
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(29)
N/A
|
(35)
-22%
|
(45)
-27%
|
(62)
-37%
|
(77)
-24%
|
(85)
-11%
|
(97)
-14%
|
(103)
-7%
|
(103)
+0%
|
(98)
+4%
|
(83)
+15%
|
(64)
+23%
|
(51)
+20%
|
(134)
-162%
|
(114)
+15%
|
(98)
+14%
|
(91)
+7%
|
5
N/A
|
(9)
N/A
|
(43)
-360%
|
(44)
-2%
|
(51)
-15%
|
(57)
-11%
|
(31)
+46%
|
(38)
-24%
|
|
Net Income | ||||||||||||||||||||||||||
Tax Provision |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
0
|
0
|
(1)
|
(1)
|
|
Income from Continuing Operations |
(29)
|
(36)
|
(45)
|
(62)
|
(77)
|
(86)
|
(97)
|
(104)
|
(103)
|
(99)
|
(84)
|
(64)
|
(52)
|
(135)
|
(115)
|
(99)
|
(92)
|
4
|
(11)
|
(44)
|
(44)
|
(51)
|
(56)
|
(31)
|
(38)
|
|
Net Income (Common) |
(29)
N/A
|
(36)
-21%
|
(45)
-27%
|
(62)
-37%
|
(77)
-24%
|
(86)
-11%
|
(97)
-14%
|
(104)
-7%
|
(103)
+1%
|
(99)
+4%
|
(84)
+15%
|
(64)
+23%
|
(52)
+19%
|
(135)
-159%
|
(115)
+15%
|
(99)
+14%
|
(92)
+7%
|
4
N/A
|
(11)
N/A
|
(44)
-308%
|
(44)
-2%
|
(51)
-14%
|
(56)
-11%
|
(31)
+45%
|
(38)
-23%
|
|
EPS (Diluted) |
-33.42
N/A
|
-40.59
-21%
|
-51.35
-27%
|
-65.88
-28%
|
-80.27
-22%
|
-90
-12%
|
-101.44
-13%
|
-106.95
-5%
|
-106.31
+1%
|
-99.64
+6%
|
-80.31
+19%
|
-47.39
+41%
|
-32.49
+31%
|
-16.64
+49%
|
-8.39
+50%
|
-7.31
+13%
|
-8.41
-15%
|
0.31
N/A
|
-0.87
N/A
|
-3.56
-309%
|
-3.63
-2%
|
-4
-10%
|
-4.35
-9%
|
-2.38
+45%
|
-2.96
-24%
|